3-acetyl-9-ethyl-9-hydroxy-4-methoxy-(9S)-2,3,9,10,13,15-hexahydro-1H,12H-benzo[ij]pyrano[3',4':6,7]indolizino[1,2-c][2,7]naphthyridine-10,13-dione

ID: ALA77707

Chembl Id: CHEMBL77707

PubChem CID: 44314252

Max Phase: Preclinical

Molecular Formula: C25H23N3O6

Molecular Weight: 461.47

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1ccc(OC)c3c1c2CCN3C(C)=O

Standard InChI:  InChI=1S/C25H23N3O6/c1-4-25(32)16-9-18-21-14(10-28(18)23(30)15(16)11-34-24(25)31)13-7-8-27(12(2)29)22-19(33-3)6-5-17(26-21)20(13)22/h5-6,9,32H,4,7-8,10-11H2,1-3H3/t25-/m0/s1

Standard InChI Key:  NSMKHAKLXAWSBU-VWLOTQADSA-N

Associated Targets(Human)

HOC-21 cell line (38 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
QG-56 (221 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

P388 (20296 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 461.47Molecular Weight (Monoisotopic): 461.1587AlogP: 2.00#Rotatable Bonds: 2
Polar Surface Area: 110.96Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 11.68CX Basic pKa: 3.02CX LogP: 0.20CX LogD: 0.20
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.45Np Likeness Score: 0.63

References

1. Sugimori M, Ejima A, Ohsuki S, Uoto K, Mitsui I, Kawato Y, Hirota Y, Sato K, Terasawa H..  (1998)  Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues.,  41  (13): [PMID:9632364] [10.1021/jm970765q]

Source